[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroenterology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroenterology":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,90,125],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644486","applying-the-intention-action-framework-to-specialty-referrals-100644486",false,"NCT07671976","Applying the Intention-Action Framework to Specialty Referrals","Reducing Low-Value Care: Applying the Intention-Action Framework to Specialty Referrals","Inclusion Criteria:\n\n* UCLA Health physicians who have made at least one specialty referral to cardiology, pulmonology, or gastroenterology for patients in UCLA Health primary care registry during July-December 2025\n\nExclusion Criteria:\n\n* Physicians who are no longer actively practicing at UCLA Health as of July 1, 2026","ALL","18 Years",{"count":19,"type":20},1600,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a prospective randomized controlled trial evaluating an EHR-embedded behavioral intervention intended to reduce low-value specialty referrals in cardiology, pulmonology, and gastroenterology. The intervention is designed to (1) strengthen physicians' intentions to avoid low-value specialty referrals at the point of encounter by presenting criteria for high-value referrals and informing physicians that referral decisions may be reviewed and (2) support follow-through on these intentions by modifying the referral process through structured checklist prompts embedded within the referral workflow.\n\nThe primary hypothesis is that physicians exposed to the intervention will demonstrate lower rates of low-value cardiology, pulmonology, and gastroenterology referrals compared with physicians exposed to the arm where the order composer allows physicians to place referrals with minimal decision support.",[26,27,28],"Cardiology","Gastroenterology","Pulmonology",[30,31,32,33,26,28,27],"Low-value referral","Behavioral science","Physician decision-making","Quality improvement","NOT_YET_RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-26","ACTUAL",{"date":40,"type":20},"2026-07-01",{"date":42,"type":20},"2027-01-31",{"name":44,"class":45},"University of California, Los Angeles","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100627960","a-study-of-barretts-esophagus-patients-optimization-of-a-risk-model-to-better-predict-the-development-of-cancer-recurrence-and-the-effect-of-risk-profile-disclosure-on-patient-quality-of-life-and-fear-of-cancer-100627960","NCT07455422","A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer","A Randomized Controlled Trial Using Endoscopic Brush Cytology and Single Cell Clonal Dynamics of Early ESOPHAGEAL ADENOCARCINOMA for Assessing Effects on Quality of Life, Cancer Worry and Defining Cost-Effective Surveillance Strategies","Endeavor-2","Inclusion Criteria:\n\n* Patients with known BE undergoing endoscopy for possible treatment by EMR or ESD due to suspicion of T1 oesophageal Barrett cancer\n* Capable of receiving informed consent and of giving permission\n* Age 18 and upward\n\nExclusion Criteria:\n\n* Patients with current known malignancy of the gastrointestinal tract other than the esophageal lesion\n* Patients refusing randomization and corresponding follow-up intervals based on biomarker profile\n* Patients with severe co-morbidity that prohibits endoscopic therapy under sedation or conscious sedation (such as severe cardiac or pulmonary disease)\n* Esophageal varices\n* Uncontrollable coagulation disorders\n* Undergoing\u002Fplanned chemotherapy or immunotherapy or received chemotherapy \\\u003C 6 months prior to endoscopy\n* Undergoing\u002Fplanned radiotherapy within the esophageal region or received radiotherapy \\\u003C 6 months prior to endoscopy\n* WHO score \\>3",{"count":56,"type":20},266,[23],"The goal of the study is:\n\n* The collection of various tissue samples (blood, biopsies and \"esophageal brushes\") and their analysis.\n* To test a risk model based on genetic analyses (DNA-FISH and so-called single cell sequencing) on esophageal tissue samples.\n* Evaluating the quality of life of Barrett's Esophagus patients and the degree of fear of getting cancer.\n\nPatients with a Barrett's Esophagus can participate in the study if they are minimally 18 years old, are capable of giving informed consent (fully understanding what the study entails before giving consent to participate), have Barrett Esophagus and are referred to one of the participating centers due to suspicion of early esophageal cancer, for which the participant will be evaluated by endoscopic imaging and biopsy.\n\nStudy procedures:\n\nAn intake consultation will be planned, wherein the eligibility criteria will be assessed, and participant characteristics will be collected.\n\nA routine gastroscopy will be planned twice during which several minimally-invasive interventions will be performed: drawing a blood sample, brush cytology during the endoscopy (a brush is used to obtain cells from the surface of the esophagus) and obtaining biopsy samples (small pieces of tissue). Each participant will need to undergo all the interventions.\n\nPatients will have to complete questionnaires at several time points to assess their quality of life (EQ-5D-DL questionnaire) and fear of cancer recurrence (Cancer Worry Scale).\n\nThis study is a randomized trial, meaning the study participants will be divided into two groups by the computer. One group will be informed of their risk profile, established based on the genetic analyses. The other group will not be informed of their risk profile. All patients will be followed-up in a more intensive surveillance schedule compared to the standard of care, for study purposes.",[60,61,62,27,63],"Barrett Esophagus","Barrett Esophagus Adenocarcinoma","Adenocarcinoma - GEJ","Gastroenterological Cancer",[60,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79],"Barrett","DNA FISH","Genetic profiling","Adenocarcinoma","Brush cytology","Cancer worry","Disease free survival","Randomized controlled trial","RCT","Endoscopic mucosal resection","Endoscopic submucosal dissection","EMR","ESD","Quality of life","Health-Economic analysis","2026-03-02",{"date":82,"type":38},"2026-03-06",{"date":84,"type":20},"2026-06-01",{"date":86,"type":20},"2030-12-31",{"name":88,"class":45},"University Hospital, Antwerp",10,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":17,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":102,"conditions":103,"keywords":110,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":46},"100594803","phase-4-comparison-of-the-effectiveness-of-paracetamol-with-ibuprofen-or-paracetamol-with-metamizole-in-treating-pain-in-acute-pancreatitis-in-children-100594803","NCT07024199","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children","Comparison of the Effectiveness of Paracetamol With Ibuprofen or Paracetamol With Metamizole in Treating Pain in Acute Pancreatitis in Children: a Randomized Trial","Inclusion Criteria:\n\n* diagnosis of AP according to the INSPPIRE mentioned above criteria,\n* age from 3 to 18 years of age,\n* abdominal pain on admission assessed on the Numerical Rating Scale (NRS) or FLACC \\>= 4 points,\n* no analgesic treatment before enrolment in the study OR the last dose of analgesic drug (paracetamol, ibuprofen, metamizole) taken ≥ 6 hours before enrolment for examination,\n* consent of legal guardians and the child (in the case of patients ≥16 years of age) to participate in the study.\n\nExclusion Criteria - patients:\n\n* who took the last dose of painkiller (paracetamol, ibuprofen, metamizole) \\\u003C 6 hours before entering the study,\n* allergic to acetylsalicylic acid, other NSAIDs, paracetamol, metamizole,\n* with inflammatory bowel disease,\n* with gastrointestinal bleeding and other active bleeding,\n* with gastric and\u002For duodenal ulcer disease,\n* chronically taking paracetamol, NSAIDs, metamizole,\n* with liver failure,\n* with heart failure according to the NYHA II-IV scale,\n* with acute and chronic renal failure,\n* with cancer,\n* whose legal guardians did not consent to participate in the study,\n* who did not consent to participate in the study (applies to patients \\> 16 years of age).","3 Years",{"count":99,"type":20},78,[101],"PHASE4","The aim of the study is to assess the effectiveness and tolerance of pain treatment in AP in children using intravenous paracetamol in combination with ibuprofen or paracetamol in combination with metamizole. The study is prospective, interventional, and randomized.",[104,105,106,107,27,108,109],"Pancreatitis, Acute","Pain, Acute","Pancreatic Disease","Pancreatic Diseases","Pancreatitis","Paediatrics",[111,112,113,114],"acute pancreatitis","acute pain","painkillers","pancreatitis","RECRUITING","2025-08-18",{"date":118,"type":38},"2025-08-24",{"date":120,"type":20},"2025-09",{"date":122,"type":20},"2027-06-01",{"name":124,"class":45},"Medical University of Warsaw",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":138,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":153},"100587035","a-randomised-clinical-investigation-to-assess-efficacy-of-low-volume-transanal-irrigation-by-qufora-irrisedo-minigo-versus-conservative-treatment-for-low-anterior-resection-syndrome-patients-100587035","NCT06923150","A Randomised Clinical Investigation to Assess Efficacy of Low Volume Transanal Irrigation by Qufora® IrriSedo MiniGo Versus Conservative Treatment for Low Anterior Resection Syndrome Patients","MINIGO","Inclusion Criteria:\n\n1. Adult aged from 18 years\n2. Patients electively treated for rectal cancer with a low anterior resection\n3. Between 3 and 18 months after the conservative colorectal surgery or 3 and 18 months after the stoma reversal if applicable\n4. LARS score \\>= 25 (minor or major LARS) (Emmertsen and Laurberg 2012) AND LARS definition as consensus with at least one symptom that results in at least one consequence (Keane et al. 2020)\n5. Adult for whom previous conservative treatments were started for at least a month\n6. Mental and physical capability of the patient to handle the MiniGo by himself.\n7. Check of the anastomosis (no signs of leakage or clinical relevant stenosis) and absence of local recurrence by Rectal digital examination of the anastomosis, any other exam used in the current practice\n8. Patient affiliated to the health social security system\n\nExclusion Criteria:\n\n1. Contra-indication to use TAI\n2. Former use of TAI (post colo-rectal surgery)\n3. Clinically relevant stenosis\n4. Current metastatic disease or local recurrence\n5. Ongoing chemotherapy\n6. Postoperative radiotherapy for rectal cancer\n7. History of diarrhoeal disease\n8. Inflammatory bowel disease\n9. Dementia\n10. Spinal cord injury, multiple sclerosis, Parkinson's disease or other significant disease assessed to be a contributory cause to LARS symptoms.\n11. Patient with cancer recurrence\n12. Patient with a life expectancy \\\u003C 1 year\n13. Participating to another clinical trial for the treatment of LARS symptom\n14. Ongoing pelvic floor rehabilitation\u002Fbiofeedback\n15. Pregnancy or intention to become pregnant during the trial period\n16. Inability and unwillingness to give informed consent",{"count":99,"type":20},"OBSERVATIONAL","The purpose of this post-market clinical follow up study is to assess the efficacy on clinical symptoms of LARS of low volume Transanal Irrigation by MiniGo in conjunction with conservative treatment versus conservative treatment at 3 months.",[27,136,137],"LARS - Low Anterior Resection Syndrome","Rectal Cancer",[139,140,141,142],"LARS","Transanal Irrigation","Minigo","rectal cancer","2025-04-03",{"date":145,"type":38},"2025-04-11",{"date":147,"type":38},"2024-06-18",{"date":149,"type":20},"2026-12",{"name":151,"class":152},"Qufora A\u002FS","INDUSTRY",9]